Coeptis Therapeutics Holdings, Inc.
COEP
$15.92
-$0.04-0.25%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -6.00% | -15.60% | -56.97% | -12.81% | 43.11% |
| Total Depreciation and Amortization | 0.10% | 0.07% | 17.42% | -6.54% | 15.39% |
| Total Amortization of Deferred Charges | -85.04% | 288.19% | 50.91% | -- | -- |
| Total Other Non-Cash Items | 49.18% | 139.36% | 120.96% | 175.20% | -121.86% |
| Change in Net Operating Assets | 24.61% | -248.37% | -398.42% | 68.08% | -597.49% |
| Cash from Operations | 10.20% | -1.29% | -64.72% | 24.10% | -33.50% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -100.00% | -- | -- | -100.00% |
| Total Debt Repaid | -- | 100.00% | -244.57% | -- | 100.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | 88.89% |
| Issuance of Preferred Stock | -100.00% | -97.65% | 666.47% | -54.40% | -9.96% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -75.00% | -- | -- | -100.00% |
| Cash from Financing | 3,947.96% | -97.95% | 733.57% | -50.37% | -24.11% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 228.18% | -160.81% | 717.85% | -44.78% | -179.42% |